

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	1	of	9	Attorney Docket Number	4172-85

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-kind Code ^{2 (if known)}	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	3,928,330	12/23/75	Ramey et al.	
	2	3,976,773	08/01/76	Curran	
	3	4,205,057	05/27/80	Whitaker	
	4	4,289,759	09/15/81	Heavner et al.	
	5	4,312,987	01/26/82	Beck	
	6	4,331,595	05/25/82	Heavner et al.	
	7	4,694,061	09/15/87	Pfeifer	
	8	4,694,081	09/15/87	MILLER ET AL.	
	9	4,806,538	02/21/89	Shimazaki et al.	
	10	4,940,709	07/10/90	Shimazaki et al.	
	11	4,992,552	02/12/91	Hubbs et al.	
	12	5,047,401	09/10/91	Lipsky et al.	
	13	5,358,938	10/25/94	Cai et al.	
	14	5,418,218	05/23/95	Wilber	
	15	5,434,151	07/18/95	Cai et al.	
	16	5,463,083	10/31/95	Biftu et al.	
	17	5,512,544	04/30/96	Wallach et al.	
	18	5,538,993	07/23/96	Mechoulam et al.	
	19	5,543,402	08/06/96	Bosies et al.	
	20	5,543,503	08/06/96	Chuntharapai et al.	
	21	5,545,404	08/13/96	Page	
	22	5,550,132	08/27/96	Benson et al.	
	23	5,578,323	11/26/96	Milstein et al.	
	24	5,648,486	07/15/97	Cai et al.	
	25	5,693,338	12/02/97	Milstein	
	26	5,700,804	12/23/97	Collins et al.	
	27	5,703,093	12/30/97	Cai et al.	
	28	5,741,809	04/21/98	Biftu et al.	
	29	5,750,530	05/12/98	Bryans et al.	
	30	5,750,565	05/12/98	Cai et al.	
	31	5,776,892	07/07/98	Counts et al.	
	32	5,780,503	07/14/98	Biftu et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	2	of	9	Attorney Docket Number	4172-85

	33	5,792,776	08/11/98	Biftu et al.	
	34	5,817,751	10/06/98	Szardenings et al.	
	35	5,834,032	11/10/98	Song	
	36	5,843,950	12/01/98	Tasaka et al.	
	37	5,856,323	01/05/99	Cai et al.	
	38	5,877,174	03/02/99	Ono et al.	
	39	5,883,227	03/16/99	Kline et al.	
	40	5,886,152	03/23/99	Nakatani et al.	
	41	5,919,785	07/06/99	Dinsmore et al.	
	42	5,932,579	08/03/99	Campbell et al.	
	43	5,976,569	11/02/99	Milstein	
	44	5,985,581	11/16/99	Nixon et al.	
	45	5,990,112	11/23/99	Campbell et al.	
	46	6,034,057	03/07/00	Dutta	
	47	6,034,221	03/07/00	Berezenko et al.	
	48	6,060,452	05/09/00	Green et al.	
	49	6,099,856	08/08/00	Milstein et al.	
	50	6,107,050	08/22/00	Alkon et al.	
	51	6,180,616	01/30/01	Fukunaga	
	52	6,222,029	04/24/01	Edwards et al.	
	53	6,248,363	06/19/01	Patel et al.	
	54	6,262,119	07/17/01	Ferrante et al.	
	55	6,265,535	07/24/01	Greene et al.	
	56	6,395,774	05/28/02	Milstein	
	57	6,441,172	08/27/02	Nefzi et al.	
	58	6,541,224	04/01/03	Yu et al.	
	59	6,677,473	01/13/04	Madison et al.	
	60	6,689,765	02/10/04	Baroudy et al.	
	61	6,967,202	11/22/05	Rao et al.	
	62	2003/0153575	08/14/03	Orme et al.	
	63	2003/0187226	10/02/03	GOODEY ET AL.	
	64	2003/0225103	12/04/03	Bar-Or et al.	
	65	2004/0038865	02/26/04	Gelber et al.	
	66	2005/0096323	05/05/05	Cheng et al.	
	67	2005/0119177	06/02/05	Bar-Or et al.	
	68	2005/0249681	11/10/05	Heidenfelder et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	3	of	9	Attorney Docket Number	4172-85

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ ; Number ⁴ ; Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	69	CS 254868	06/11/87	VANZURA JIRI RNDR CSC		
	70	DE 19937721	02/15/01	PLANCK GESELLSCHAFT		(partial translation)
	71	EP 0043219	01/06/82	ORTHO PHARMA CORP		
	72	EP 0216746	04/01/87	MONSANTO CO		
	73	EP 0493812	07/08/92	AJINOMOTO KK		
	74	EP 0557388	09/01/93	UNIV COMPANY PTY LTD		
	75	EP 0655060	05/31/95	XENOVA LTD		
	76	EP 610943	08/17/94	URIACH & CIA SA J		
	77	EP 939124	09/01/99	SMITHKLINE BEECHAM PLC		
	78	FR 2717484	09/22/95	PF MEDICAMENT		
	79	GB 2263109	07/14/93	BRITISH BIO TECHNOLOGY		
	80	JP 10-226615	08/25/98	POLA CHEM IND INC		(Translated Abstract)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	4	of	9	Attorney Docket Number	4172-85

	81	JP 10245315	09/14/98	VANZURA JIRI RNDR CSC		(translated abstract)
	82	JP 2000327575	11/28/00	TEIKA SEIYAKU KK		(translated abstract)
	83	JP 3176478	07/31/91	SNOW BRAND MILK PROD CO LTD		(translated abstract)
	84	JP 63290868	11/28/88	FUJISAWA PHARMACEUTICAL CO		(translated abstract)
	85	NZ 335544	08/31/01	NEURONZ LTD		
	86	WO 02/062797	08/15/02	CELLTECH R & D INC		
	87	WO 02/12201	02/14/02	DMI BIOSCIENCES INC		
	88	WO 2000/057187	09/28/00	UNIV VANDERBILT		
	89	WO 91/14378	10/03/91	NUTRASWEET CO		
	90	WO 93/08815	05/13/93	CYTOVEN		
	91	WO 94/04512	03/03/94	XENOVA LTD		
	92	WO 94/04513	03/03/94	XENOVA LTD		
	93	WO 94/04537	03/03/94	CYTOMED INC		
	94	WO 94/20063	09/15/94	CYTOVEN INT NV		
	95	WO 95/18610	07/13/95	CYTOMED INC		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	5	of	9	Attorney Docket Number	4172-85

	96	WO 96/00212	01/04/96	CYTOMED INC		
	97	WO 96/00391	01/04/96	AFFYMAX TECH NV		
	98	WO 96/10396	04/11/96	EMISPHERE TECH INC		
	99	WO 97/12625	04/10/97	CYTOVEN J V		
	100	WO 97/36888	10/09/97	MERCK & CO INC		
	101	WO 97/48685	12/24/97	GLAXO GROUP LTD		
	102	WO 99/40931	08/19/99	UNIV GEORGETOWN		
	103	WO 99/49865	10/07/99	MAYO FOUNDATION		
	104	WO 99/51720	10/14/99	CYTRAN LTD		

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. ¹	
	105	AKIYAMA ET AL., Neurobiol. Aging (2000), 21, pages 383-421
	106	Alvarez et al., "Isolation and Structure Elucidation of Two New Calpain Inhibitors from Streptomyces Griseus"; J. Antibiotics, 47(11):1195-1201 (November 1994)
	107	Arbabi et al., "Priming Interleukin 8 Production: Role of Platelet-Activating Factor and p38"; Arch Surg., 134(12):1348-1353 (December 1999); 15pgs.
	108	Au et al., "Effect of PDE4 Inhibitors on Zymosan-Induced IL-8 Release From Human Neutrophils: Synergism with Prostanoids and Salbutamol"; Br. J. Pharmacol, 123:1260-1266 (1998)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	6	of	9	Attorney Docket Number	4172-85

	109	Balk, "Lesson 24, Volume 12 – ARDS: Pathophysiology of SIRS and MODS" www.chestnet.org/education/pccu/vol12/lesson24.html , pp. 1-19, printed 7/20/2000
	110	Barrow et al., WIN 64821, a New Competitive Antagonist to Substance P, Isolated from an Aspergillus Species: Structure Determination and Solution Conformation"; J. Org. Chem., 58:6016-6021 (1993)
	111	Binisti et al.; "Structure-Activity Relationships in Platelet Activating Factor"; J. Lipid Mediat. Cell Signal; (January 1997); Vol. 15(2); pp. 125-144 (Abstract)
	112	BRAUNS, et al., Anticancer Research 24:1713-20 (2004)
	113	Chan et al., "Site-Specific N-Terminal Auto-Degradation of Human Serum Albumin"; Eur. J. Biochem., 227:524-528 (1995)
	114	Cytokines and Autoimmune Diseases, edited by Kuchroo, et al., 2002, Humana Press Inc., Totowa, NJ, pages 3-23, 389-406
	115	DATABASE WPI Section Ch, Week 199844 Derwent Publications Ltd., London, GB; Class B03, AN 1998-515050 XP002369751
	116	Davidson et al. "Autoimmune Diseases", N. Engl. J. Med (2001) 345(5), pages 340-350
	117	DIRR, K. ET AL: "The transformation of arginine into citrulline" Z. PHYSIOL. CHEM. , 237, 121-30, 1935
	118	FADEN et al., J. Cerebral Blood Flow & Metabolism 23:355-63 (2003)
	119	FADEN, et al., J. Alzheimer's Dis. 6:S93-S97 (2004)
	120	FADEN, et al., J. Cerebral Blood Flow & Metabolism 23:342-54 (2003)
	121	Gross et al., "Regulation of Interleukin-8 Production in a Human Colon Epithelial Cell Line (HT-29); Gastroenterology, 108:653-661 (1995)
	122	Hayashi et al., "Synthetic Hexa- and Heptapeptides That Inhibit IL-8 from Binding to and Activating Human Blood Neutrophils1"; J. Immunol., 154:814-824 (1995)
	123	ISHII, et al. Toxicology Letters, 7:433-37 (1981)
	124	JACKSON I M D ET AL: "AMYOTROPHIC LATERAL SCLEROSIS TRH AND HISTIDYLPROLINE DIKETOPIPERAZINE IN THE SPINAL CORD AND CEREBROSPINAL FLUID" NEUROLOGY, vol. 36, no. 9, 1986, pages 1218-1223, XP008090473 ISSN: 0028-3878
	125	KAAKKOLA SEPPO; WURTMAN RICHARD J: "Effects of two diketopiperazines, cyclo (His-Pro) and cyclo (Asp-Phe), on striatal dopamine: A microdialysis study" BRAIN RESEARCH BULLETIN, vol. 32, no. 6, 1993, pages 667-672, XP002369690

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	7	of	9	Attorney Docket Number	4172-85

	126	Kulikov et al., "Review: The Bioregulatory Role of Platelet-Activating Factor in Intracellular Processes and Cell – Cell Interactions", www.protein.bio.msu.su/biokhimiya/contents/v63/full/63010057.html, pp. 1-13 (1997)
	127	McCAIN, et al. Int. J. Immunopharmac. 8(4):443-46 (1986)
	128	McCAIN, et al., Life Science, 41:169-76 (1987)
	129	MeSH, "Autoimmune Diseases", internet document <<http://www.ncbi.nlm.nih.gov/sites/entrez>>, accessed 10/31/07, 2 pages
	130	Miller et al., "Peptide Inhibitor of Interleukin-8 (IL-8) Reduces Staphylococcal Enterotoxin-A (SEA) Induced Neutrophil Trafficking to the Lung"; Inflamm. Res., 45:393-397 (1996)
	131	MILNE, et al. J. Pharm. Pharmacol., 50:1331-37 (1998)
	132	Nitecki et al., J. Org. Chem., 33(2):864-866 (1968).
	133	Palacios et al., "Tenidap Decreases IL-8 and Monocyte Chemotactic Peptide-1 (MCP-1) mRNA Expression in the Synovial Tissue of Rabbits with Antigen Arthritis and in Cultured Synovial Cells"; Clin. Exp. Immunol., 111:588-596 (1998)
	134	PRASAD C ET AL: "Increased cerebrospinal fluid cyclo(His-Pro) content in schizophrenia." NEUROPEPTIDES NOV 1991, vol. 20, no. 3, November 1991 (1991-11), pages 187-190, XP002477203 ISSN: 0143-4179
	135	PURVES ET AL., Life: the Science of Biology, 3rd Ed. (1992), page 376
	136	Rainger et al., "Endothelial-Borne Platelet-Activating Factor and Interleukin-8 Rapidly Immobilize Rolling Neutrophils"; Am. J. Physiol., 272(Heart Circ. Physiol. 41):H114-H122 (1997)
	137	Rainsford et al., "Effects of 5-Lipoxygenase Inhibitors on Interleukin Production by Human Synovial Tissues in Organ Culture: Comparison with Interleukin-1-Synthesis Inhibitors"; J. Pharm. Pharmacol., 48:46-52 (1996)
	138	Roth et al., "Platelet-Activating Factor Exerts Mitogenic Activity and Stimulates Expression of Interleukin 6 and Interleukin 8 in Human Lung Fibroblasts via Binding to its Functional Receptor"; J. Exp. Med., 184:191-201 (1996)
	139	SAKURADA et al. J. Pharm. Pharmacol., 34:750-51 (1982)
	140	Sakuta et al., "Dual Regulatory Effects of Interferon- α , - β , and - γ on Interleukin-8 Gene Expression by Human Gingival Fibroblasts in Culture Upon Stimulation with Lipopolysaccharide from Prevotella Intermedia, Interleukin-1 α , or Tumor Necrosis Factor- α "; J. Dent Res., 77(8):1597-1605 (1998)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	8	of	9	Attorney Docket Number	4172-85

	141	Sano et al. "Process Research and Development of L-Alanyl-L-Glutamine, a Component of Parenteral Nutrition", Organic Process Research & Development, 2000, Vol. 4, pages 147-152
	142	Shimazaki et al., "Diketopiperazine Derivatives, a New Series of Platelet-Activating Factor Inhibitors"; Chem. Pharm. Bull., 35(8):3527-3530 (1987)
	143	Shimazaki et al., "Diketopiperazines as a New Class of Platelet-Activating Factor Inhibitors"; J. Med. Chem., 30:1706-1709 (1987)
	144	Shimazaki et al., "PAF Inhibitory Activity of Diketopiperazines: Structure-Activity Relationships"; Lipids, 26(12):1175-1178 (1991)
	145	Smith et al., "Lesson 10, Volume 12 – Asthma: Evolving Anti-Inflammatory Therapy", www.chestnet.org/education/pccu/vol12/ lesson10.html, pp. 1-8, printed 7/20/2000
	146	Smith et al., Bioorg. Med. Chem., 8:2369-2374 (1998)
	147	Smith et al., Darlington. Mult. Scler. (1999) 5, pages 110-120
	148	t'Hart et al., "DDT (2004) 9(12), page 517-524
	149	The Cytokine Handbook, edited by Thomson and Lotze, 4th edition, 2003 Academic Press, Volume I, London, UK, pages 167-199, 456-474, 567-601
	150	The Cytokine Handbook, edited by Thomson and Lotze, 4th edition, 2003 Academic Press, Volume II, London, UK, pages 838-860 and 1189-1211
	151	UNAL et al., Brain Research, 747(1):52-59 (1997)
	152	WALTER et al. Proc. Natl. Acad. Sci. 72:
	153	Yoshida et al., "PAF Inhibitors of Microbial Origin"; Prog. Biochem. Pharmacol., 22:68-80 (1988)
	154	International Search Report for International (PCT) Patent Application No. PCT/US03/31226, mailed June 14, 2005 (Attorney's Ref. No. 4172-85-PCT)
	155	International Preliminary Examination Report for International (PCT) Patent Application No. PCT/US03/31226, mailed November 29, 2005 (Attorney's Ref. No. 4172-85-PCT)
	156	Examiner's First Report for Australian Patent Application No. 2003279761, mailed June 16, 2008 (Attorney's Ref. No. 4172-85-PAU)
	157	Supplementary Partial European Search Report for European Patent Application No. 03773099, mailed May 6, 2008 (Attorney's Ref. No. 4172-85-PEP)
	158	Examination Report for New Zealand Patent Application No. 539735, mailed May 10, 2006 (Attorney's Ref. No. 4172-85-PNZ)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/679,699
				Filing Date	10-02-2003
				First Named Inventor	Bar-Or
				Art Unit	1649
				Examiner Name	EMCH, GREGORY S
Sheet	9	of	9	Attorney Docket Number	4172-85

	159	Examination Report for New Zealand Patent Applicaion No. 542886, mailed November 28, 2007 (Attorney's Ref. No. 4172-84-PNZ)
	160	Examination Report for New Zealand Patent Application No. 539735, mailed January 10, 2008 (Attorney's Ref. No. 4172-85-PNZ)
	161	Examination Report for New Zealand Patent Application No. 539735, mailed May 20, 2008 (Attorney's Ref. No. 4172-85-PNZ)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.